SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as traders debate its potential for a breakout, driven by speculative enthusiasm, community-led social media campaigns, and anticipation for future regulatory clarity. Discussion remains heavily focused on the coin's historical volatility and its status as a bellwether for meme-coin market sentiment during broader altcoin activity.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is experiencing heightened community engagement driven by aggressive accumulation and discussions surrounding institutional adoption through new derivatives products. While some traders are focused on short-term volatility and technical support levels, the broader community remains active with bullish sentiment, citing long-term growth potential and comparisons to other leading layer-one ecosystems.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is capturing significant community attention as traders highlight its ecosystem growth, including new protocol integrations and increased staking engagement, while speculative interest in various meme tokens on the chain drives high social media activity. Market participants remain focused on potential price breakouts, with many actively debating whether upcoming macro developments will fuel a sustained move toward higher valuation levels.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is trending as the community debates its technical setup and long-term potential amidst broader altcoin market volatility. Traders are actively discussing the token's price action, volume trends, and its place within the current meme coin landscape as they look for signs of a breakout.

The KARRAT protocol is a decentralized gaming infrastructure layer, supported by $KARRAT and empowered by a truly decentralized community with a shared vision embracing gaming, entertainment and AI products catering for the new era.  To accelerate the evolution of gaming, entertainment, and AI-driven experiences with blockchain technology and a truly empowered community.  The KARRAT protocol pioneers a decentralized framework in gaming and entertainment, combining blockchain with community-driven collaboration. $KARRAT can animate ecosystems of games and products and the protocol makes tools available to support these industries and the adoption of KARRAT technology provides a unique, personalized gaming experience.

KARRAT

KARRAT is drawing significant investor interest as the community anticipates a breakout driven by its deep integration with the My Pet Hooligan gaming ecosystem and strategic AI partnerships. While some debate the long-term potential amid token dilution concerns, many traders are actively accumulating the token, viewing current levels as a strong entry point ahead of anticipated Web3 gaming adoption.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is gaining significant market attention as traders actively discuss its potential for a major breakout, with community members highlighting its status as an established meme token that is seeing renewed momentum. Discussions are currently centered on its recent exchange visibility, the persistence of its fan base, and a broader rotation of capital into high-beta small cap assets.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is experiencing significant bearish sentiment as it trades near multi-year lows, fueling community debates between long-term holders awaiting a potential breakout and critics dismissing the asset as obsolete. Conversations are heavily focused on the lack of upward momentum, the impact of broader market trends, and high-conviction retail investors who are choosing to DCA despite the persistent downward price action.

StupidCoin

StupidCoin is gaining significant traction within the memecoin community as supporters highlight its perceived potential for viral growth and unique community-driven culture. Investors are actively discussing the asset's technical momentum and its ecosystem developments, often framing it as a standout project within the broader Solana-based meme sector.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is seeing a surge in community discussion following a period of intense volatility and triple-digit gains that have sparked renewed interest among retail traders. While some investors are highlighting the potential for future growth and technical breakouts, others remain skeptical, debating whether the movement represents a genuine turnaround or just another speculative pump.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is drawing significant interest as institutional inflows remain strong, with market participants debating whether current levels represent a structural accumulation phase or a precursor to further volatility. The community is actively discussing Bitcoin's resilience amid broader geopolitical uncertainties and examining how ETF liquidity and leverage dynamics are shaping the asset's short-term price discovery.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>Tariffs on drugs imported from countries with which the U.S. has tariff deals, such as the European Union, South Korea, Japan, and UK, will be capped at 15%.</li><li>The White House said that the duties will apply to products made by certain large pharma companies in 120 days while smaller ones will get 60 more days.</li></ul> President Donald J. Trump on Thursday signed an executive order imposing a 100 percent tariff on imported patented pharmaceuticals and active pharmaceutical ingredients, citing a national-security threat from America’s heavy dependence on foreign supply chains, as the administration seeks to increase manufacturing in the country.Pharmaceutical ETFs iShares US Pharmaceuticals ETF (IHE) and VanEck Pharmaceutical ETF (PPH) closed 0.75% and 0.45%, respectively, following the announcement.<h2 class="st-heading-2">New Levies</h2>Despite leading the world in pharmaceutical research and development, U.S. produces only 15 percent of the active pharmaceutical ingredients it uses for patented medicines and imports 53 percent of the finished patented products themselves, the White House said.The new levies apply to patented drugs made in countries with which the U.S. have no tariff deals and by companies that haven’t inked drug pricing deals with the administration. Tariffs on drugs imported from countries with which the U.S. has tariff deals, such as the European Union, South Korea, Japan, and UK, will be capped at 15%.The White House said that the duties will apply to products made by certain large pharma companies in 120 days while smaller ones will get 60 more days.<h2 class="st-heading-2">How Can Companies Avoid These Levies?</h2>Companies can sharply reduce or avoid the tariff by committing to onshore production or signing drug pricing agreements with the Department of Health and Human Services, Trump said.Firms that submit approved onshoring plans will initially face only a 20 percent tariff. Those inking pricing agreements with the government and onshoring production will pay no tariffs at all through Jan. 20, 2029, Trump said.Several companies have already inked drug pricing agreements with the Trump administration, including Merck, Pfizer and Eli Lilly and Company, leaving select big names and many small and mid-sized pharma companies exposed.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IHE">IHE</a> and <a href="https://stocktwits.com/symbol/PPH">PPH</a> stayed within the ‘neutral’ territory coupled with ‘normal’ message volume.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-tumbles-following-q1-delivery-miss-street-weighs-in/cZ7U4aORI8H">TSLA Stock Tumbles 5% Following Q1 Delivery Miss — Street Weighs In On Demand, Potential Discounts, AI Strategy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

President Donald Trump delivers his State of the Union address to a joint session of Congress in the chambers of the U.S. House of Representatives in Washington, DC on February 24, 2026. 

Trump Slaps 100% Tariffs On Imported Patented Drugs, Sparing Companies That Onshore Or Cut Prices

The new levies apply to patented drugs made in countries with which the U.S. have no tariff deals and by companies that haven’t inked drug pricing deals with the administration.

Equity

The new levies apply to patented drugs made in countries with which the U.S. have no tariff deals and by companies that haven’t inked drug pricing deals with the administration.


<ul class="summary-bullets"><li>Pharmaceutical companies from the European Union, Japan, South Korea, Switzerland, and the U.K. will be subject to separate tariff rates under the bilateral deals they have entered into with the U.S.</li><li>Earlier, a Bloomberg report said the Trump administration could announce new pharma tariffs as early as Thursday.</li><li>The report stated that there may be exemptions for drugs used to treat certain diseases.</li></ul>The Trump administration is reportedly preparing to impose tariffs of up to 100% on drugs from pharmaceutical companies that have not yet struck deals with the White House.According to a CNBC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/04/02/trump-pharmaceutical-tariffs-100percent.html">report</a>, the new tariffs will be imposed on both branded drugs and their active ingredients. However, companies can avoid these tariffs if they move their manufacturing to the U.S. or are currently negotiating a deal with the Trump administration.The&nbsp;<a href="https://stocktwits.com/symbol/PPH">VanEck Pharmaceutical ETF</a> (PPH) and the&nbsp;<a href="https://stocktwits.com/symbol/IHE">iShares U.S. Pharmaceuticals ETF</a> (IHE) were both down about 1% at the time of writing.<h2 class="st-heading-2">Generic Drugs To Escape Additional Tariffs, Says Report</h2>The report added that generic drugs will not be subject to any additional tariffs.Pharmaceutical companies from the European Union, Japan, South Korea, Switzerland, and the U.K. will be subject to separate tariff rates under the bilateral deals they have entered into with the U.S., the report stated.Earlier, a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-04-01/trump-administration-readies-new-tariffs-on-select-drugmakers">report</a> said the Trump administration could announce new pharma tariffs as early as Thursday. The report added that there may be exemptions for drugs used to treat certain diseases. President Trump is scheduled to sign executive orders at 2 p.m. ET on Thursday, but it is not yet known what those orders will be.The report added that these tariffs result from an investigation under Section 232 of the Trade Expansion Act. This rule addresses imports of a product that threatens the national security of the U.S.<h2 class="st-heading-2">Several Major Pharma Companies Have Struck Deals Already</h2>Several major pharmaceutical companies struck deals with the Trump administration in 2025 to lower the prices of their new and existing drugs in the U.S.This&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/abbvie-merck-top-drugmakers-lower-us-drug-prices-trump-mfn-deal/cLeitzkREsG">includes</a> giants such as Eli Lilly &amp; Co. (LLY), Novo Nordisk A/S (NVO), Pfizer Inc. (PFE), and GSK Plc. (GSK), and Merck &amp; Co. Inc. (MRK), among others.“As of today, 14 out of the 17 largest pharmaceutical companies… but they've all agreed… have now agreed to drastically lower drug prices for their American patients… for the American people and patients,” President Trump said, while announcing the deals in December 2025.In October 2025, President Trump said Pfizer would adopt most-favored-nation pricing for all new drugs launched in the U.S. The company launched its medicines on the TrumpRx portal in February 2026.In November 2025, Eli Lilly and Novo Nordisk struck an agreement with the Trump administration to cut prices on select upcoming pills and existing obesity drugs. Eli Lilly’s Zepbound, Novo Nordisk’s Ozempic, and Wegovy are available on the TrumpRx portal.Meanwhile, U.S. equities declined in Thursday morning’s trade. At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was down 0.22%, while the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) declined 0.34%. Retail sentiment on Stocktwits regarding the S&amp;P 500 ETF was in the ‘extremely bearish’ territory.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/owl-stock-sinks-blue-owl-blocks-4-2b-redemptions/cZ7xHowRI8h">OWL Stock Sinks After Blue Owl Reportedly Blocks Nearly $4.2B In Redemptions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Donald Trump is seen during the his departure the White House en route Hebron, Kentucky on March 11, 2026, in Washington DC, United States. (Photo by Celal Gunes/Anadolu via Getty Images)

Trump Administration Prepares Up To 100% Pharma Tariffs On Drugs From Companies That Have Not Struck A Deal Yet: Report

Pharmaceutical companies can avoid these tariffs if they move their manufacturing to the U.S. or are currently negotiating a deal with the Trump administration.

Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move

Eli Lilly's $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven pharma space. 

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

U.S. Food and Drug Administration vaccine chief Vinay Prasad is reportedly leaving the agency at the end of April.The Wall Street Journal <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/fdas-controversial-vaccines-chief-will-leave-the-agency-7fe59aa3">reported</a> the upcoming departure on Friday, citing FDA Commissioner Marty Makary.Shares of select pharmaceutical companies with whom Prasad has sparred with during his tenure rallied on the news. Shares of Moderna (<a href="https://stocktwits.com/symbol/MRNA">MRNA</a>) traded 3% higher after hours while uniQure (<a href="https://stocktwits.com/symbol/QURE">QURE</a>) stock rallied 50%. Shares of Sarepta Therapeutics (<a href="https://stocktwits.com/symbol/SRPT">SRPT</a>) also gained 5% in extended hours of trading.Makary said that federal health officials are now on the lookout for a replacement for Prasad who led the Center for Biologics Evaluation and Research (CBER) at the FDA. He was responsible for reviewing certain cancer drugs, gene therapies, and other treatments in addition to vaccines.<h2 class="st-heading-2">Prasad’s Shaky Tenure</h2>During his tenure, Prasad faced several disputes pertaining to drug reviews.Earlier this year, Prasad refused to consider an application seeking approval for Moderna’s flu shot but the agency later <a href="https://stocktwits.com/news-articles/markets/equity/moderna-stock-fda-accepts-revised-flu-vaccine-application-for-review/cZR0MwoR4v1">pivoted</a> after Moderna agreed on another confirmation study post-approval.Most recently, the FDA has gone up against uniQure’s gene therapy for ⁠Huntington's disease. The agency has <a href="https://stocktwits.com/news-articles/markets/equity/why-did-qure-stock-almost-halve-pre-market-today/cZd344CRIcD">recommended</a> that the company conduct a sham-surgery-controlled study after disagreeing with other study data submitted.Prasad previously <a href="https://stocktwits.com/news-articles/markets/equity/fda-official-who-halted-sarepta-s-gene-therapy-resigns-amid-backlash-over-access-to-duchenne-treatment/choQYmjR5yz">resigned</a> in July 2025 merely months into the job following controversies over decisions on Sarepta Therapeutics’ Elevidys gene therapy for Duchenne muscular dystrophy. Prasad was brought back shortly afterwards.<h2 class="st-heading-2">Reasons For Exit</h2>Regarding Prasad’s departure this term, Makary reportedly said that he had only intended to remain at the agency during his period of absence at the University of California.As per the agency commissioner, all policies that Prasad wanted to help implement have now been announced, including a new priority program to expedite the application review process for treatments that meet national priorities.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/incyte-drug-approved-in-europe-for-treating-yet-another-rare-cancer/cZdLgTHRI49">Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

QURE, SRPT, MRNA Shares Rally On Report Of Vinay Prasad’s FDA Exit

The Wall Street Journal reported the upcoming departure on Friday, citing FDA Commissioner Marty Makary.

TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint

TBPH company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

<ul class="summary-bullets"><li>Makary urged the Trump administration to partner with the pharmaceutical industry.&nbsp;</li><li>The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind.&nbsp;</li><li>As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.</li></ul>The U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Wednesday reportedly warned that the country is falling behind its Asian rival China in drug development.Makary, in an <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/02/18/fda-chief-warns-us-is-losing-ground-to-china-in-early-drug-trials.html">interview</a> with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind. Makary recommended that the Trump administration partner with the pharmaceutical industry “to help them deliver more cures and meaningful treatments for the American public.”As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.<h2 class="st-heading-2">FDA’s Efforts</h2>Last year, the FDA initiated a program called the Commissioner's National Priority Voucher program in a bid to expedite the review of certain drug applications. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.So far, over 15 drugs from various pharma companies have been awarded the voucher and while one has been approved, another has also been rejected.Earlier this month, FDA refused to approve Disc Medicine’s bitopertin oral tablets for the treatment of Erythropoietic Protoporphyria despite tapping the drug for fast review.However, the agency approved Augmentin XR manufactured by USAntibiotics in December after granting it the voucher. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/IHE"> iShares U.S. Pharmaceuticals ETF</a> (IHE) stayed within the ‘neutral’ territory coupled with ‘normal’ message volume.The ETF closed marginally in the red on Wednesday but has gained about 29% over the past 12 months.Meanwhile, Invesco Pharmaceuticals ETF (PJP) and State Street SPDR S&amp;P Pharmaceuticals ETF (XPH) added 26% and 27%, respectively.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/carvana-dismisses-short-seller-allegations-as-misleading/cZRK3kWR4wG">Carvana Dismisses Short Seller Allegations As Misleading: Retailer’s Q4 Earnings Disappoint Wall Street</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

<ul class="summary-bullets"><li>The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S.&nbsp;</li><li>With this step, ART100 moves from regulatory clearance to active commercial availability, the company said.</li><li>Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business</li></ul>Shares of Inspira Technologies OXY (IINN) popped over 28% in pre-market trading on Monday after Israel’s largest health services provider approved the procurement of its FDA-cleared ART100 platform.<a href="https://stocktwits.com/symbol/IINN">IINN shares</a> gave up premarket gains and fell around 3% after the opening bell.&nbsp;The company secured approval from Clalit Health Services’ Medical Equipment Committee, allowing its INSPIRA ART100 system to be immediately procured and deployed across a healthcare network serving roughly 4.9 million members.<h2 class="st-heading-2">ART100 Regulatory Clearance</h2>With this step, ART100 moves from regulatory clearance to active commercial availability, marking a significant growth opportunity for Inspira and strong clinical validation.“By securing this approval, we are laying the foundation for potentially long-term, high-quality revenue. This validation from a world-class, data-driven health ecosystem serves as a powerful reference case as we accelerate our commercialization efforts in the U.S. and other global markets,” said Dagi Ben-Noon, CEO of Inspira Technologies.The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and for (Extracorporeal Membrane Oxygenation) ECMO procedures outside the U.S.<h2 class="st-heading-2">Top U.S. Medical Center Clears ART100&nbsp;</h2>In January, Inspira Technologies’ ART100 system completed clinical evaluation at a top U.S. academic medical centre and moved into the budgeted procurement stage. The system successfully treated about 30 patients across surgeries, transplants, and other critical procedures, leading to its adoption into routine clinical workflows.&nbsp;With the evaluation phase now closed, the hospital has begun an internal process to purchase multiple ART100 units, pending final budget approval.Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business. The transaction also includes a planned $15 million strategic equity investment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.The stock has shed around 25% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did IINN Stock Surge 28% In Pre-Market Today?

The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members.

<ul class="summary-bullets"><li>Hims &amp; Hers said the compounded copy uses the same active ingredient as Wegovy but features a different formulation and delivery system.</li><li>The compounded pill will start at the introductory pricing for the first month for qualifying new customers under a five-month plan.</li><li>The pill is engineered to preserve the active ingredient during digestion and improve absorption.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) rose 10% on Thursday after the company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.Hims &amp; Hers said the compounded copy uses the same active ingredient as Wegovy but features a different formulation and delivery system from the FDA-approved oral semaglutide. Novo Nordisk originally introduced Wegovy as a once-weekly injection and expanded the franchise earlier this year with the launch of an oral pill version.<h2 class="st-heading-2">$100 Cheaper Than Novo’s Wegovy</h2>Hims &amp; Hers said treatment plans using the compounded pill will start at an introductory $49 for the first month for qualifying new customers under a five-month plan. The remaining months are priced at $99 per month, payable in advance.According to Novo Nordisk’s website, Wegovy pills are priced at $149 per month for a 1.5 mg dose.Hims &amp; Hers stated that its compounded pill is engineered to preserve the active ingredient during digestion and improve absorption, offering an alternative for patients who want to avoid injections.Meanwhile, NVO shares fell nearly 6%.<h2 class="st-heading-2">Novo’s Pricing Challenges</h2>Earlier this week, Novo said it expects adjusted sales for full year 2026 to drop between 5% and 13%, with operating profit potentially falling by 13% due to pricing pressure, intensifying competition, and upcoming patent expiries for key ingredients in Wegovy and Ozempic in select markets outside the U.S.“Our 2026 guidance reflects a year of unprecedented pricing pressure,” CEO Mike Doustdar said in a call with journalists on Wednesday. Doustdar added that Novo would have to accept short-term pain to lift volumes, arguing that lowering prices would pay off in the long-run.The pill variant has already seen significant traction since its launch in January.“I can tell you, as of this week, we have over 170,000 people that are on the Wegovy pill, and most of that is self-pay,” Doustdar said in a call with analysts.Eli Lilly (LLY), the maker of weight-loss drugs Mounjaro and Zepbound, saw its shares fall 6.5%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/HIMS">HIMS</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while chatter was ‘extremely high’ on the platform.One user saw the new launch as a “trend changing event.”<stembedurl>https://stocktwits.com/Dr_Stoxx/message/644091407</stembedurl>Another bullish user highlighted HIM’s latest developments.<stembedurl>https://stocktwits.com/tothebulltothewall/message/644092695</stembedurl>Year-to-date, the stock has declined around 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-b-stock-is-falling-despite-q4-beat/cZbZB3uR4VV">Barrick’s Q4 Earnings Beat Expectations – So, What Is Dragging The Stock Down In Premarket Today?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling?

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.

HIMS Stock Rises On Low-Cost Wegovy Alternative, Raising New Pricing Questions For Novo And Lilly

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.



<ul class="summary-bullets"><li>Eli Lilly issued a revenue guidance between $80 billion and $83 billion for fiscal 2026</li><li>For the full year 2025, Eli Lilly’s revenue grew 45% to $65.18 billion.</li><li>CFO Lucas Montarce said the company expects to launch the multidose Zepbound within the next 30 days, according to a Bloomberg report.</li></ul>Shares of Eli Lilly (LLY) jumped 8% in pre-market trading on Wednesday, after the company reported better-than-expected fourth-quarter results and issued a revenue guidance between $80 billion and $83 billion for fiscal 2026, significantly above fiscal 2025 revenue.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 9.2% after the opening bell.Fourth-quarter revenue surged 43% to $19.3 billion, driven by volume growth from Mounjaro and Zepbound – signalling sustained momentum in its obesity and diabetes portfolio. Analysts had expected a revenue of $17.86 billion, according to Fiscal.ai data. Meanwhile, Q4 earnings increased by 51% to $7.39 per share on a reported basis, compared to Street estimates of $7.22 per share.For the full year, Eli Lilly’s revenue grew 45% to $65.18 billion. LLY expects earnings of $33.50 to $35 per share for full-year 2026.<h2 class="st-heading-2">Mounjaro And Zepbound Drive Revenue Growth</h2>Global revenue for Mounjaro surged 110% to $7.4 billion in Q4 2025, with U.S. sales rising 57% to $4.1 billion on strong demand despite lower realized prices. International revenue jumped to $3.3 billion from $899 million a year earlier, driven mainly by volume growth.U.S. Zepbound revenue climbed 122% to $4.2 billion, fueled by higher demand but partially offset by pricing pressure. Meanwhile, revenue from Verzenio, Eli Lilly’s drug to treat metastatic breast cancer, edged up 3% to $1.6 billion.<h2 class="st-heading-2">Eli Lilly’s Product Pipeline</h2>After the FDA authorized Lilly to market Zepbound in a multidose device last month, CFO Lucas Montarce said the company expects to launch the multidose pen within the next 30 days, according to a report by Bloomberg on Wednesday.In an interview with CNBC last month, CEO Dave Ricks said the upcoming Medicare coverage for obesity drugs could significantly boost the launch of its experimental weight-loss pill, Orforglipron. Ricks added that the company expects Medicare coverage to begin immediately after the drug’s launch.<h2 class="st-heading-2">LLY Pulls Ahead As NOVO Faces Headwinds</h2>Eli Lilly’s optimistic outlook stands in stark contrast to Novo Nordisk (NVO), which expects adjusted sales to decline between 5% and 13% and operating profit to drop by up to 13%. The company cited pricing pressure, intensifying competition, and upcoming patent expiries for the key ingredients in Wegovy and Ozempic in select markets outside the U.S.“This is just more evidence they are dominating the category,” Mizuho’s Jared Holz told Bloomberg of Eli Lilly’s obesity market position. “Novo is playing from behind and everyone knows it.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/LLY_jpg_1dcca688cf.webp" alt="LLY.jpg" width="933" height="102"><figcaption>LLY's Sentiment Meter and Message Volumes on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that Lilly proved that with “a good product comes great demand.”<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/643931351</stembedurl>LLY shares have gained around 25% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-fda-higher-dose-wegovy-nvo-stock-outlook/cZbjThlR4ZM">Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

LLY Stock Surges On Q4  Beat – Obesity, Diabetes Drugs Drive Strong FY26 Outlook

LLY Stock - Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

iShares Trust - iShares U.S. Pharmaceuticals ETF

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Current Price	$87.43
Prev Close	$88.67
Open	$88.89
Dividend Yield	N/A
50-Day Moving Average	$87.14
Beta	N/A
Avg. Volume	99,281.67
PE Ratio	N/A

52-Week High	$92.30
52-Week Low	$62.02
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IHE
iShares U.S. Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IHE News

IHEiShares U.S. Pharmaceuticals ETF